NVCR News and Press, NovoCure Limited From 06/02/20

Novocure (NASDAQ: NVCR) today announced the launch of MyLink, a new tool that allows patients to download their Optune usage data from the comfort of home without the need for an in-person visit by a Novocure Device Support Specialist. Novocure initiated a phased launch with an initial wave o...

COVID-19 Pandemic Sorrento Therapeutics (SRNE), a San Diego-China biotech, reported that its anti-SARS-CoV-2 antibody, STI-1499, completely inhibited SARS-CoV-2 virus infection from interacting with the ACE2 receptor after four days of incubation (see story ). In preclinical studies, the mo...

Optune is the first innovative treatment for glioblastoma approved in China in over 15 years A large, global phase 3 pivotal clinical study in newly diagnosed glioblastoma showed adding Optune to chemotherapy more than doubled the five-year overall survival rat e 1 Optune is Za...

Investment thesis NovoCure (NVCR) has made impressive progress in developing and commercialising its novel and innovative Tumor Treating Fields therapy technology, which uses electric fields tuned to specific frequencies to disrupt solid tumor cancer cell division, administered via a head-wo...

Image source: The Motley Fool. NovoCure Limited   (NASDAQ: NVCR) Q1 2020 Earnings Call May 2, 2020 , 10:00 p.m. ET Operator Continue reading

Axcella Health (NASDAQ: AXLA ) initiated with Buy rating and $10 (115% upside) price target at BTIG Research. More news on: Axcella Health Inc., Viking Therapeutics, Inc., Y-mAbs Therapeutics, Inc., Healthcare stocks news, Stocks on the move, Read more ...

NovoCure Limited (NVCR) Q1 2020 Earnings Conference Call April 30, 2020 08:00 AM ET Company Participants Ashley Cordova - Senior Vice President of Finance & Investor Relations William Doyle - Executive Chairman Asaf Danziger - Chief Executive Officer Wilco Groenhuysen - Chi...

The following slide deck was published by NovoCure Limited in conjunction with their 2020 Q1 earnings Read more ...

NovoCure (NASDAQ: NVCR ): Q1 GAAP EPS of $0.04 beats by $0.02 . More news on: NovoCure Limited, Earnings news and commentary, Healthcare stocks news, Read more ...

Quarterly net revenues of $101.8 million, representing 39 percent growth versus the first quarter 2019 and 3 percent growth versus the fourth quarter 2019 Balance sheet strength allows continued investments in innovation and the advancement of commercial and development priorities ...